From Earlier: Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE

Loading...
Loading...
Santarus, Inc.
SNTS
today announced that it has commenced promotion of prescription FENOGLIDE® (fenofibrate) tablets 40 mg and 120 mg to selected physicians in the U.S. FENOGLIDE is indicated as an adjunct to diet to reduce elevated low-density lipoprotein-cholesterol (LDL-C), total cholesterol, triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein-cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia. FENOGLIDE also is indicated as an adjunct to diet for treatment of adult patients with hypertriglyceridemia.
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...